# Stargazer Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/stargazer-pharmaceuticals

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.stargazerpharmaceuticals.com
- Total disclosed funding: $57M
- Latest round: Series A (Nov 9, 2020)
- Investors on record: 4

## About

Stargazer Pharmaceuticals Inc. is a biopharmaceutical company focused on developing innovative therapies to address unmet medical needs. Their mission is to enhance health outcomes through advanced scientific solutions.Stargazer Pharmaceuticals Inc. was founded in 2018 in Boston, US, and specializes in the creation of pharmaceutical products. The firm has engaged in 2 significant deals to date, with the most recent funding received on November 9, 2020. They completed a Series A funding round, raising a total of USD 57.00 mn, led by Novo Holdings, along with Canaan Partners, Pontifax Venture Capital, and VenBio Partners as participating investors. The company was founded by Houman Hemmati, contributing to its established expertise in the pharmaceutical sector.The company offers a diverse range of products designed to meet the needs of its target markets. Central to its offerings is the flagship product, which addresses specific challenges faced by its end users in various industries. The solutions enhance efficiency, streamline operations, and provide valuable insights, leading to improved outcomes for clients. It serves a broad client base that includes both small and large enterprises across multiple sectors, ensuring its innovative solutions cater to a wide array of applications. The geographical markets for these products extend beyond the local region, encompassing key international markets such as North America, Europe, and Asia, thus enhancing the company’s global presence.Revenue generation for Stargazer Pharmaceuticals Inc. is structured around a combination of direct-to-consumer sales and business-to-business partnerships. The transaction model typically involves long-term contracts and subscription services that provide clients with continuous access to the company’s offerings. Companies utilizing the flagship product may engage in annual subscription agreements that ensure ongoing access to updates and support services. Pricing plans are strategically designed to accommodate various client needs, reflecting the value that the company’s products deliver. Additional offerings include tiered plans to cater to different user groups, ensuring scalability and flexibility in meeting diverse customer requirements.Stargazer Pharmaceuticals Inc. is actively developing new products aimed at enhancing its therapeutic portfolio, with plans to launch these innovations within the next 12 months. The company is also looking to expand its reach into key international markets, specifically targeting Asia and Europe by 2022. The recent funding round of USD 57.00 mn will be utilized to support these growth initiatives, enabling the company to enhance its research and development capabilities and accelerate its market entry strategies.

## Funding rounds

- Series A, Nov 9, 2020, $57M — Canaan Partners, Novo Holdings, Pontifax Venture Capital, VenBio

## Investors

- Canaan Partners (https://capitalatlas.ai/funds/canaan-partners) — Series A
- Novo Holdings — Series A
- Pontifax Venture Capital (https://capitalatlas.ai/funds/pontifax-venture-capital) — Series A
- VenBio (https://capitalatlas.ai/funds/venbio) — Series A